<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460820</url>
  </required_header>
  <id_info>
    <org_study_id>DRBX201901/PRO</org_study_id>
    <nct_id>NCT04460820</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection</brief_title>
  <official_title>A Randomized,Open-label, Single-Dose,Two-Cycle,Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized,Open-label, Single-Dose,Two-Cycle,Cross- Bioequivalence Study of Doxorubicin
      Hydrochloride Liposome Injection Under Advanced Breast Cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection , 20 mg:10 mL (CSPC OuYi
      Pharmaceutical Technology Co, Ltd), and Caelyx®, 20 mg:10 mL (Janssen-Cilag International
      NV), in Advanced Breast Cancers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 15 days post-adminstration</time_frame>
    <description>The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 15 days post-adminstration</time_frame>
    <description>The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 15 days post-adminstration</time_frame>
    <description>The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Doxorubicin Hydrochloride Liposome Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg/m2 ,IV on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin Hydrochloride Liposome Injection(Caelyx®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg/m2 ,IV on Day 1 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride Liposome Injection</intervention_name>
    <description>50mg/m2,IV on Day 1 of each cycle</description>
    <arm_group_label>Doxorubicin Hydrochloride Liposome Injection</arm_group_label>
    <arm_group_label>Doxorubicin Hydrochloride Liposome Injection(Caelyx®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Voluntary agreement to provide written informed consent. 2.Patients with locally
             advanced or metastatic breast cancer diagnosed by histology or cytology，and who may
             benefit from monotherapy of Doxorubicin liposomes.

             3.Females age 18 to 75 years, inclusive. 4.Body weight ≥45.0 kg, and BSA＜1.80m2. 5.The
             ECOG performance status is 0 to 2. 6.The expected survival time is more than 3 months.
             7.Subjects must have laboratory values within the limits described below: ANC ≥1.5 x
             109/L PLT ≥100 x 109/L HB ≥90 g/L PT/INR and APTT ≤1.5 x ULN Cr ≤1.5 x ULN Serum total
             bilirubin ≤1.5 x ULN(OR ≤3 X ULN for subjects with liver metastases) AST (SGOT) and
             ALT (SGPT) ≤2.5 x ULN (OR ≤5 X ULN for subjects with liver metastases) 8.The subjects
             had no pregnancy plan and volunteered to use effective contraception and had no egg
             donation plan within 6 months after entering the study.

             9.The subject will be able to communicate well with the investigator and understand
             and comply with the requirements of the study.

        Exclusion Criteria:

          -  1.Significant allergy, hypersensitivity or idiosyncratic reactions to doxorubicin
             and/or any related compounds.

             2.Treatments were terminated due to treatment failure or serious adverse reactions in
             subjects who had previously used doxorubicin liposomes.

             3.Patients with severe cardiovascular, lung, liver, kidney, gastrointestinal,
             endocrine, immune system, skin, musculoskeletal, neurological or psychiatric
             conditions that the researchers did not consider appropriate for inclusion.

             4.Patients who had undergone major surgery within 3 months before screening, or
             planned to undergo major surgery during the study period.

             5.Having a history of alcoholism, drug abuse or drug abuse. 6.The results of alcohol
             breath test were more than 0.0mg/100ml or drug abuse screening was positive
             (Methamphetamine, ketamine, MDMA,Tetrahydrocannabinol).

             7.Pregnant or breast-feeding female. 8.Positive result to any of the following:
             HIV-1/2, hepatitis B and C; syphilis.

             9.Study drug prior to radiation or the use of chemotherapy drugs less than 28 days, or
             other antineoplastic therapy (e.g., endocrine therapy, Chinese medicine treatment, the
             local radiotherapy of pain relief, etc.) is less than 14 days, or during the study
             period need to merge the other anti-tumor drug treatment.

             10.Impaired cardiac function: QTc＞470ms; LVEF（left ventricular ejection fraction）
             below 50% or below institutional normal at screening; Congestive heart failure of
             grade≥ 2 from NYHA classification, myocardial infarction or uncontrolled angina
             pectoris occurred within 6 months before enrollment; Have had bypass surgery; 11.
             Blood donation or massive blood loss within 90 days before screening (&gt; 400ml) .

             12.The total cumulative dose of doxorubicin was ≥300mg/m2 before screening, or
             previous administration of anthracycline caused severe cardiotoxicity.

             13.Eating a specific diet (such as grapefruit) within 48 hours prior to enrollment can
             affect drug absorption, distribution, metabolism, and excretion.

             14.Participating in other clinical trials and accepting clinical trial drugs within 28
             days prior to enrollment.

             15.Other researchers judged unsuitable for participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

